[Effect of CDK1 Interferes with the Regulation of PLK1, Aurora B and TRF1 on the Proliferation of Leukemia Cells].

OBJECTIVE: To investigate the clinical characteristics, diagnosis and treatment of 1 case EBV negative extranodal NK/T cell lymphoma (ENKTL) patients. METHODS: The clinical manifestations, diagnosis and treatment of one case ENKTL patients with EBV negative were analyzed retrospectively. RESULTS: A 46-year-old woman diagnosed as positive for exosanal NK/T cell lymphoma (EBER+) in September 2016 was treated by 6 courses of CHOEP regimen chemotherapy and local nasopharyngeal radiotherapy, without regular follow-up review. On March 20, 2020, the patient was admitted to our hospital for multiple rashes and rupture of the right knee joint for morethan 2 months. Histopathology showed inflammatory exudation and necrotic tissue, atypia lymphocytes were observed, and part of them were grew around the blood vessels. Immunohistochemistry showed: heterotypic lymphocytes CD3 (partial +) , CD43+, CD20-, PAX-5-, CD4-, CD8-, CD56+, GrB+, TIA-1+, Ki-67 (10%+) , and chromogenic in situ hybridization (CISH): EBER-, the patient was diagnosed as recurrent NK/T cell lymphoma (nasal type) stage IV B group (CA stage) and skin involvement of NK/T cell lymphoma by combining PET-CT, bone marrow cell morphology, flow cytometry, chromosome karyotype analysis and TCR rearrangement, etc. On April 4, 2020, the patient was treated by CEOP-L regimen (4 courses) and central lymphoma prophylactic intrathecal chemotherapy. PET-CT re-examination showed the patient achieved PR, and the treatment regimen was changed to Gemos-L regimen. CONCLUSION: EBV negative ENKTL is rare in clinic and easy to be misdiagnosed, so it should be distinguished from peripheral T cell lymphoma. This case was treated with EBV positive ENKTL regimen, with good short-term efficacy.

[Clinical Analysis of Patient with Esophageal Granulocytic Sarcoma Derived from Chronic Myelocytic Leukemia].

OBJECTIVE: To investigate the diagnosis and treatment of esophageal granulocytic sarcoma derived from chronic myelocytic leukemia (CML). METHODS: The clinical manifestations, diagnosis and treatment of 1 case of esophageal granulocytic sarcoma secondary from chronic myelocytic leukemia were retrospectively analyzed and the related literature was reviewed. RESULTS: The patient was a 72-year-old woman with poststernal pain accompanied by general weakness. Gastroscopy was performed in a local hospital. At the same time, the increase of peripheral blood leucocytes was obvious. Under gastroscopy, 1.0 cm×0.5 cm irregular protuberance was found at 28 cm from the esophagus to the incisor teeth, and the surface was covered with erosion and a small amount of blood. Pathological results showed that heterotypic lymphoid cell infiltration, cytoplasmic red staining and more neutrophils were seen. Immunohistochemical staining results showed that AE1/AE3, CK5/6 and p63 displayed squamous epithelium (+); atypical lymphoid cells CD20-, CD23-, CD3-, CD5-, CD79a-, MP0+, Ki-67+ (80%) were observed; FISH examination showed positive expression of BCR/ABL. The patient was further examined on myelogran and was diagnosed as chronic myelocytic leukemia with esophageal granulocytic sarcoma. Imatinib was given orally and the patient was followed up in the clinic. CONCLUSION: Esophageal granulocytic sarcoma is rare in clinic, its clinical symptoms are not specific. Gastroscopy should be routinely screened for esophageal discomfort, and the esophageal granulocytic sarcoma derived from CML is treated according to the therapeutic regimen of the acute transformation of chronic myelocytic leukemia.